Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding (HALT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by Cook
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: February 17, 2011
Last updated: November 13, 2015
Last verified: November 2015

February 17, 2011
November 13, 2015
December 2011
March 2017   (final data collection date for primary outcome measure)
Proportion of patients with further bleed [ Time Frame: 72 Hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01306864 on ClinicalTrials.gov Archive Site
Proportion of patients with initial hemostasis [ Time Frame: At the conclusion of the index procedure ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding
Clinical Evaluation of Hemospray: Hemostasis of Active GI Luminal Tract Bleeding
The objective of this study is to show that Hemospray is effective in achieving initial hemostasis and documenting rate of further bleed when compared to standard of care.
Not Provided
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Bleeding Peptic Ulcers
Device: Hemospray Kit
Hemostasis of Arterial GI Bleeding
Other Name: Endoscopic Hemostasis
Experimental: Hemospray Treatment
Hemospray Kit
Intervention: Device: Hemospray Kit
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2017
March 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Bleeding peptic ulcer

Exclusion Criteria:

  • Patient is: < 18 years of age
  • Patient is unable to consent
  • Patient is contraindicated to undergo endoscopy
  • Patient has: coagulopathy, altered post surgical anatomy of the stomach, previously placed intrahepatic portosystemic shunt
  • Patient is pregnant or lactating
  • Patinet has an INR > 2.5
18 Years and older
Contact: Travis Conley 765-463-7537 tconley@medinst.com
Contact: Malin Tygesen 45 202 325 75 Malin.tygesen@cookmedical.com
Canada,   Hong Kong,   Netherlands,   United Kingdom
Not Provided
Not Provided
Principal Investigator: Joseph Sung, MD Prince of Wales Hospital, Shatin, Hong Kong
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP